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Current immunotherapies against cancer comprise of
target specific antibodies, cellular therapies like activated
immune cells (e.g. DCs or NK cells), vaccination strate-
gies, the use of tumour-specific infectious agents like
oncolytic viruses or a combination thereof including
conventional chemotherapies. All of those approaches
attempt to target cancer specific pathways or certain
immune response mechanisms, which have to be acti-
vated or at least present in the individual patient. This
requires the identification of predictive biomarker and /
or the execution of large clinical trials. Recent reports
have shown that most clinical responses to targeted
therapies are still quite unpredictable and yield in large
clinical trials to demonstrate any benefit over conven-
tional therapies.
Therefore there is still an unmet medical need to
develop new therapies, identify novel target structures in
cancer or combine different therapies to optimise the
patient’s outcome. Cell-based therapies as a pharmaceuti-
cal delivery tool for drugs or genes are expected to
improve clinical medicine and the inflammatory tumour
microenvironment (iTME) could be a novel target. We
have combined those to innovative approaches to use
mesenchymal stem cells (MSCs) delivering a gene
directly into the iTME and activated a cytotoxic prodrug
such as Ganciclovir only in the context of the tumour or
its metastasis. This increases the local anti-tumour effi-
cacy and reduces unwanted off-target toxicities. A first
clinical trial (TREAT-ME1) targeting adenocarcinomas of
the GI tract is currently being conducted.
Although the idea to use cells as pharmaceutical com-
pounds is not new, the clinical application of Cell Ther-
apeutics represents a new challenge for clinical scientists
and all pharmaceutical applicants with regard to the
current regulatory requirements for manufacturing,
quality control and clinical trial approval in many parts
of the world. The guidelines and standards are currently
harmonized within the EU / FDA area of responsibility.
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